Fiche société
First Affiliated Hospital Xi'an Jiaotong University
Traitements, essais et publications liés.
Traitements4programmes
Essais1liés
Publications12liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ET1402L1-ARTEMIS™ T cells -intra-hepatic arteryClinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ ) hepatocellular carcinoma (HCC). | Cancer | Phase 1 | Immunomodulation | China | À vérifier |
| ET1402L1-ARTEMIS™ T cells -Intratumoral InjectionsClinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ ) hepatocellular carcinoma (HCC). | Cancer | Phase 1 | Immunomodulation | China | À vérifier |
| ET1402L1-ARTEMIS™ T cells -IVClinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ ) hepatocellular carcinoma (HCC). | Cancer | Phase 1 | Immunomodulation | China | À vérifier |
| ET1402L1-ARTEMIS™ T cells -IVClinical study to evaluate safety (primary objectives) and efficacy (secondary objective) of ET1402L1-ARTEMIS™2 T cells in patients with alpha fetoprotein positive (AFP+ ) hepatocellular carcinoma (HCC). | Cancer | Phase 1 | Immunomodulation | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ET1402L1-ARTEMIS™ T cells -IV | Cancer | Phase 1 | NCT03888859 | ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma | COMPLETED |
Publications
12| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| ET1402L1-ARTEMIS™ T cells -Intratumoral Injections | CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. | International immunopharmacology | ||
| ET1402L1-ARTEMIS™ T cells -Intratumoral Injections | Modulated electro-hyperthermia enhances tumor cell susceptibility to γδ T cell-mediated cytotoxicity and tumor infiltration in NOD/SCID xenograft models. | International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group | ||
| ET1402L1-ARTEMIS™ T cells -Intratumoral Injections | Prolonged intratumoral treatment with TLR7/8 agonist R848 regulates the tumor immune microenvironment resulting in enhanced antitumor activity. | Cancer biology & therapy | ||
| ET1402L1-ARTEMIS™ T cells -IV | Novel captopril-valproic acid platinum(IV) hybrids with potent antiproliferative and antimetastatic activities targeting fibrosis and DNA-repair. | European journal of medicinal chemistry | ||
| ET1402L1-ARTEMIS™ T cells -IV | Broad cross-T cell immunity between emerging SARS-CoV-2 serotypes waved by spike-signature mutations. | Emerging microbes & infections | ||
| ET1402L1-ARTEMIS™ T cells -IV | Immune evasion in locally advanced mismatch repair-deficient microsatellite instability-high colorectal cancer: Reduced T-cell infiltration and upregulation of epithelial IDO1 expression. | Oncoimmunology | ||
| ET1402L1-ARTEMIS™ T cells -Intratumoral Injections | Armed Oncolytic Myxoma Virus Induces Systemic Antitumor Immunity Against Solid Tumors in Immunocompetent Mice. | Research square | ||
| ET1402L1-ARTEMIS™ T cells -Intratumoral Injections | The closer, the better: intratumoral delivery of a thermoresponsive gemcitabine-loaded hydrogel in preclinical PDAC models. | Drug delivery and translational research | ||
| ET1402L1-ARTEMIS™ T cells -intra-hepatic artery | [Selective effectiveness of galactose-containing liposome IL-2 on liver lymphocytes]. | Gan to kagaku ryoho. Cancer & chemotherapy | ||
| ET1402L1-ARTEMIS™ T cells -intra-hepatic artery | In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial. | Oncoimmunology | ||
| ET1402L1-ARTEMIS™ T cells -IV | Apatinib enhances targeted immunotherapy the IL-6-gp130-PI3K pathway in HER2-positive gastric cancer. | Cancer biology & medicine | ||
| ET1402L1-ARTEMIS™ T cells -IV | FGFR2 fusion-driven cholangiocarcinoma is characterized by a distinct neutrophil-enriched tumor microenvironment in a syngeneic murine model. | JHEP reports : innovation in hepatology |